Predicting cancer outcomes remains challenging due to the heterogeneity of the disease. Factors such as tumor biology, patient health, and treatment response contribute to this uncertainty. Statistical models and prognostic biomarkers are tools used to estimate survival and recurrence risks, but they cannot account for every variable, leading to a range of possible outcomes.
